Eric Jean Marie Leire
Founder presso GENFLOW BIOSCIENCES PLC
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Eric Jean Marie Leire is the founder of Genflow Biosciences Plc, which was founded in 2020.
He is currently the Chief Executive Officer & Director of Renovaro Biosciences Denmark ApS, Director of Novicol International Holding, Inc., Director of Immunethep SA, Independent Director of OSE Immunotherapeutics SA, Director of Inhatarget Therapeutics, Director of Bsim Therapeutics Ltd., and Independent Director of PHAXIAM Therapeutics SA. He previously held positions such as President & Chief Executive Officer of APT Therapeutics, Inc., Chief Executive Officer of Cantex Pharmaceuticals, Inc., Chief Executive Officer of Renovaro, Inc., Chief Executive Officer & Director of DKTI A and Dandrit Corp.
Pte Ltd., Division Director of Pfizer Inc. and Schering-Plough Corp., Director of Genizon Biosciences, Inc., Director, Chief Executive & Financial Officer of Renovaro, Inc., Director of Biohemp International, Inc., Director of FIT Biotech Oy, Director of Egalet Ltd., and Partner of Medwell Capital Corp.
He was also a Member-Supervisory Board of Pherecydes Pharma SA and a Research Associate at Harvard Aids Initiative.
Dr. Leire holds an MBA from École des Hautes Études Commerciales de Paris, a doctorate from the University of Grenoble, an MBA from Institut Supérieur des Affaires, and an MBA from Kellogg School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GENFLOW BIOSCIENCES PLC
42.53% | 03/04/2024 | 124 414 999 ( 42.53% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Eric Jean Marie Leire
| Società | Posizione | Inizio |
|---|---|---|
| GENFLOW BIOSCIENCES PLC | Founder | - |
| OSE IMMUNOTHERAPEUTICS | Director/Board Member | 22/06/2023 |
| PHAXIAM THERAPEUTICS S.A. | Director/Board Member | 23/06/2023 |
Immunethep SA
 Immunethep SA BiotechnologyHealth Technology Immunethep SA develops biological products. It specializes in anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. The company was founded by Pedro Madureira and Bruno Santos and is headquartered in Cantanhede, Portugal. | Director/Board Member | 01/01/2018 |
| Bsim Therapeutics Ltd. | Director/Board Member | 01/05/2019 |
Inhatarget Therapeutics
 Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Director/Board Member | 01/08/2020 |
| Novicol International Holding, Inc. | Director/Board Member | - |
Renovaro Biosciences Denmark ApS
 Renovaro Biosciences Denmark ApS Miscellaneous Commercial ServicesCommercial Services Dandrit Biotech A/S conducts clinical research, trading, and manufacturing for the pharmaceutical industry. It focuses on research and development of medicines. The company was founded on April 1, 2001 and is headquartered in Hørsholm, Denmark. | Chief Executive Officer | 01/04/2011 |
Precedenti posizioni note di Eric Jean Marie Leire
| Società | Posizione | Fine |
|---|---|---|
| RENOVARO INC. | Chief Executive Officer | 07/01/2019 |
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formazione di Eric Jean Marie Leire
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
| University of Grenoble | Doctorate Degree |
| Institut Supérieur des Affaires | Masters Business Admin |
| Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| RENOVARO INC. | Health Technology |
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| GENFLOW BIOSCIENCES PLC | Health Technology |
| PHAXIAM THERAPEUTICS S.A. | Health Technology |
| Aziende private | 18 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Medwell Capital Corp.
 Medwell Capital Corp. Investment ManagersFinance Medwell Capital Corp. operates as an investment and advisory firm which directly invests in and advises companies on strategy and corporate and technology development. It also provides clinical, regulatory and corporate advisory services. The company was founded on December 15, 1998 and is headquartered in Edmonton, Canada. | Finance |
APT Therapeutics, Inc.
 APT Therapeutics, Inc. Medical SpecialtiesHealth Technology APT Therapeutics, Inc. manufactures hospital equipment. Its products include X-ray equipment, tubes & related irradiation equipment, Medical X ray film illuminator screens, Medical X ray film transfer cases, Medical X ray film illuminator clips and more. The company was founded by Ridong Chen in 2001 and is headquartered in St. Louis, MO. | Health Technology |
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Health Technology |
Cantex Pharmaceuticals, Inc.
 Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cantex Pharmaceuticals, Inc. develops heparin to ameliorate cardiac ischemia-reperfusion injuries. It also develops medications to enhance the safety and effectiveness of existing cancer treatments. The firm provides Disulfiram + copper Chelate that includes non-overlapping cancer stem cell killing mechanisms of actions. The company was founded in 2013 by Thomas P. Kennedy, Neil William Flanzraich and Stephen G. Marcus and is headquartered in Weston, FL. | Health Technology |
Biohemp International, Inc.
 Biohemp International, Inc. Pharmaceuticals: MajorHealth Technology Biohemp International, Inc. operates as a pharmaceutical company, which provides insomnia remedy. The firm has developed Zleepax, which is a sleep aid with beta blockers as the major active agent. The company was founded by Briger Jan Olsen on August 11, 2012 and is headquartered in New York, NY. | Health Technology |
FIT Biotech Oy
 FIT Biotech Oy BiotechnologyHealth Technology FIT Biotech Oy engages in the business of researching, developing, and manufacturing diagnostic laboratory tests and pharmaceutical products. The firm is also involved in marketing gene transport unit vector technology to be used as a gene transport mechanism in gene therapeutic applications. The company was founded on May 17, 1995 and is headquartered in Tampere, Finland. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Egalet Ltd.
 Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Health Technology |
DKTI A/S
 DKTI A/S Investment Trusts/Mutual FundsMiscellaneous DKTI A/S is a closed-end investment fund. It engages in the investment on listed bonds, financial instruments, securities, stocks, and liquid assets. The company was founded on January 22, 2007 and is headquartered in Copenahgen, Denmark. | Miscellaneous |
Pherecydes Pharma SA
 Pherecydes Pharma SA Pharmaceuticals: MajorHealth Technology Pherecydes Pharma SA is a biotechnology company, which engages in the research and development of anti-infective therapies based on the use of bacteriophages. It develops phage treatments of bacterial infections. The company was founded by Jerome Gabard and Manuel Gea in December 2006 and is headquartered in Romainville, France. | Health Technology |
Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS Miscellaneous Commercial ServicesCommercial Services Dandrit Biotech A/S conducts clinical research, trading, and manufacturing for the pharmaceutical industry. It focuses on research and development of medicines. The company was founded on April 1, 2001 and is headquartered in Hørsholm, Denmark. | Commercial Services |
| Dandrit Corp. Pte Ltd. | |
| Novicol International Holding, Inc. | |
Immunethep SA
Immunethep SA BiotechnologyHealth Technology Immunethep SA develops biological products. It specializes in anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. The company was founded by Pedro Madureira and Bruno Santos and is headquartered in Cantanhede, Portugal. | Health Technology |
| Harvard Aids Initiative | |
Inhatarget Therapeutics
Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Health Technology |
| Bsim Therapeutics Ltd. |
- Borsa valori
- Insiders
- Eric Jean Marie Leire
